MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease

    R. Miller, A. Li, M. Campbel, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

    Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether…
  • 2023 International Congress

    Is a Parkinson’s Sialorrhoea service effective?

    C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)

    Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…
  • 2023 International Congress

    Experience of Quality of Life in German Persons living with Parkinson’s Disease: A Qualitative Exploration

    M. van Munster, M. Stührenberg, A. Pedrosa Carrasco, D. Pedrosa (Marburg, Germany)

    Objective: It seems essential to understand how people with Parkinson´s disease (PwPD) experience quality of life (QoL) and to which domains they assign particular importance.…
  • 2023 International Congress

    Trial site factor in Parkinson’s disease (PD) diary non-compliance

    P. Reksoprodjo (Prague, Czech Republic)

    Objective: In this analysis, we wanted to explore if PD diary non-compliance is distributed randomly in the dataset or if it has a tendency to…
  • 2023 International Congress

    Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction

    T. Schirinzi, D. Maftei, P. Grillo, R. Bovenzi, J. Bissacco, C. Simonetta, H. Zenuni, FM. Passali, S. Di Girolamo, A. Stefani, NB. Mercuri, R. Lattanzi, C. Severini (Rome, Italy)

    Objective: To elucidate the role of Substance P in PD through molecular characterization of patients’ olfactory neurons. Background: Substance P is a neuropeptide largely expressed…
  • 2023 International Congress

    Does Cognitive Complaint in Parkinson’s Disease Reflect in Neuropsychological Testing?

    C. Catiul, S. Lopez, V. Mishra (Birmingham, USA)

    Objective: To investigate whether the neuropsychological tests differ among participants with Parkinson’s disease (PD) presenting with the subjective cognitive complaint (PD-SCC) and PD with normal…
  • 2023 International Congress

    An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder

    G. Schneider, A. Avidan, D. Bliwise, S. Criswell, E. During, J. Elliott, L. Forsberg, J-F. Gagnon, M. Howell, D. Huddleston, A. Keil, J. Lee-Iannotti, M. Lim, J. Mcleland, M. Miglis, E. Mignot, R. Postuma, C. Schenck, D. Shprecher, E. ST. Louis, A. Videnovic, B. Boeve, Y-E. Ju, J. Fields (Rochester, USA)

    Objective: To apply an algorithmic approach to interpretation of cognitive data to assess cognitive impairment in RBD participants. Background: Cognitive changes in emerging neurodegenerative disease…
  • 2023 International Congress

    DaT-Scans Have Limited Utility in Predicting Treatment Response to Ventriculoperitoneal Shunts in Normal Pressure Hydrocephalus

    J. Ma, M. Hamed, D. Victor, T. Kay, M. Salgado (Brooklyn, USA)

    Objective: To determine usefulness of DaT-SPECT imaging in the management of normal pressure hydrocephalus (NPH). Background: Dopamine transporter single-photon emission computed tomography (DaT-SPECT) imaging is…
  • 2023 International Congress

    Subjective cognitive complaints in participants of the Healthy Brain Ageing (HeBA) study

    S. Jónsdóttir, C. Pauly, O. Tsurkalenko, E. Thiry, AM. Hanff, T. Marques, C. Horlings, A. Garrido, C. Vega, S. Schade, P. Mahlknecht, C. Gomes, S. Ghosh, K. Rege, R. Rawal, D. Mcintyre, K. Seppi, M. Martí, C. Trenkwalder, E. Tolosa, W. Poewe, V. Satagopam, R. Krüger, B. Mollenhauer (Heisdorf, Luxembourg)

    Objective: To investigate the prevalence of subjective cognitive complaints (SCC) from Healthy Brain Ageing Study (HeBA) participants in Luxembourg, and explore risk factors prevalence which…
  • 2023 International Congress

    modulation of sodium potassium ATPase activity by norepinepherine and serotonin to find an effective cure of parkinson’s disease by introducing the novel concept of insilico drug repurposing

    S. Sinha (Prayagraj, India)

    Objective: Parkinson's disease can cause neuropsychiatric disturbances which can range from mild to severe. This includes disorders of speech, cognition, mood, behaviour, and thought. In addition to…
  • « Previous Page
  • 1
  • …
  • 615
  • 616
  • 617
  • 618
  • 619
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley